Bristol Myers Squibb's CheckMate-9DW trial shows combination of Opdivo and Yervoy improves survival for advanced hepatocellular carcinoma patients.
Bristol Myers Squibb's phase 3 CheckMate-9DW trial has met its primary endpoint, showing that a combination of Opdivo and Yervoy improved overall survival for advanced hepatocellular carcinoma patients compared to sorafenib or lenvatinib. The combination treatment demonstrated a manageable safety profile and will be fully evaluated before presenting results at an upcoming medical conference.
March 20, 2024
8 Articles